Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: META stock price vs WST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WST's multiple
Needs WST P/E.
Implied fair value · at META's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Meta Platforms, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
WEST PHARMACEUTICAL SERVICES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Apple Inc.
META vs AAPL
AMAZON COM INC
META vs AMZN
NVIDIA CORP
META vs NVDA
Alphabet Inc.
META vs GOOGL
MICROSOFT CORP
META vs MSFT
Snap Inc
META vs SNAP
APTARGROUP, INC.
META vs ATR
BECTON DICKINSON & CO
META vs BDX
ICU MEDICAL INC/DE
META vs ICUI
TELEFLEX INC
META vs TFX
BAXTER INTERNATIONAL INC
META vs BAX
CARDINAL HEALTH INC
META vs CAH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe META can sustain its current growth and margin profile, then META looks attractive to own because it is fundamentally stronger than WST yet trades at a lower P/E and lower EV/EBITDA multiple.
On a P/E basis, META trades at 28.1x versus WST at 51.2x, even though META has much stronger growth and margins, which makes META look cheaper on earnings power. The model’s implied price of $1,203.70 is 103.9% above the current price of $590.24, with the current price also sitting below the historical band of $594.08-$726.10 and far below the DCF range of $314.36-$425.31 shown in the data.
Supporting Metrics
